Drug Trial Radar · NCT06823232
A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men
Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Nov 6, 2024
Primary completion
Dec 5, 2024
Study completion Dec 5, 2024
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this clinical trial is to quantitatively analyse the total radioactivity in the excreta of subjects after oral administration of \[14C\]XY0206, and to obtain data on human radioactive excretion rate and main excretion routes and the radioactivity of human plasma, urine, and faeces after oral administration of \[14C\]XY0206 by subjects Metabolite profiling, identification of major metabolites, determination of metabolic pathways and elimination pathways; Subjects who met the criteria fasted for at least 10h before administration and took \[14C\]XY0206 suspension (containing about 37.5mg/100µCi\[14C\]XY0206) orally on an empty stomach in the morning of the first day of administration (DI).Subjects will also complete urine, stool and blood collection within a specified period of time。
Conditions
- Metabolism of Radioactive Substances
Interventions
[14C]XY0206Drug
On the morning of the day of medication (D1), the subject took \[14C\] XY0206 suspension orally on an empty stomach (containing approximately 37.5 mg/100 µ Ci \[14C\] XY0206).
Primary outcomes
What the sponsor says the trial is designed to measure.
- excrementTime frame: 22 days
- Radioactive blood sampleTime frame: 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Gaobo Hospital, Life Science Park Road, Changping District, Beijing
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.